Navigation Links
Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
Date:2/20/2013

The research was published early in the January issue of the journal Technology in Cancer Research and Treatment. The article describes experiments using ultrasonic molecular imaging (USMI) and Dynamic Contrast Enhanced-Perfusion Imaging (DCE-PI) to measure response to therapy for pancreatic cancer.

Paul Dayton, PhD, senior author says, "What we found is that using two non-invasive technologies, we can detect response to therapy earlier than by relying on tumor volume changes. Having new non-invasive, inexpensive technologies available to measure response to therapy earlier during the course of treatment would be a significant advance in the ability to tailor a person's treatment to improve outcomes."

Dr. Dayton, an Associate Professor of Biomedical Engineering, worked with Jen Jen Yeh, MD, Associate Professor of Surgery and Pharmacology, to evaluate the imaging technologies on human pancreatic cancer in a pre-clinical model. Both faculty are members of the Lineberger Comprehensive Cancer Center.

USMI has the ability to characterize non-invasively the biologic processes at the cellular and molecular levels. It does this through the use of targeted contrast agents, which are markers that bind to specific proteins expressed on cancer cells within the body. These contrast agents enable a standard ultrasound system to detect signals from cancer cells that would otherwise be undetectable.

Ultrasound DCE-PI is a method used to non-invasively monitor the blood flow in the microcirculation. Since growing tumors require abnormally increased blood flow, changes in blood vessel structure or density can provide information regarding tumor malignancy.

The team used a drug that inhibits a protein specific to tumors. They then used the imaging tools to measure the response of two different tumors, one known to respond to the drug therapy, and a second known not to respond. The results indicated that USMI was able to detect molecular signs of tumor response to therapy after only 2 days. A change in blood flow in the tumor was observed to detect response after day 14 using DCE-PI. Over the same period, standard volume measurements were not able to detect therapeutic response, and prior studies suggested that volume measurements do not become indicative of response until approximately 28 days. Thus, these methods showed a notable improvement in the early identification of tumor response to therapy, using contrast enhanced ultrasound imaging.

Although the contrast agents for USMI are not yet available in the United States, they are currently in clinical trials in Europe for cancer imaging.


'/>"/>

Contact: Dianne Shaw
dgs@med.unc.edu
919-966-7834
University of North Carolina Health Care
Source:Eurekalert  

Related biology news :

1. Preclinical studies use specialized ultrasound to detect presence of cancer
2. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
3. Virology researcher awarded nearly $2 million to study chronic hepatitis E
4. New study shows how seals sleep with only half their brain at a time
5. Study shows that diet of resistant starch helps the body resist colorectal cancer
6. Breakthrough study opens door to broader biomedical applications for Raman spectroscopy
7. Phosphorus starvation linked to symptoms of citrus disease Huanglongbing in new study
8. Yale Study links common chemicals to osteoarthritis
9. CU-Boulder amphibian study shows how biodiversity can protect against disease
10. Busy beavers give Canada geese a lift, study shows
11. Video study shows which fish clean up coral reefs, showing importance of biodiversity
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
(Date:2/2/2016)... , Feb. 2, 2016   Parabon ... from the U.S. Army Research Office and the ... range and sensitivity of the company,s Snapshot ... Accounting Mission and, more generally, defense-related DNA forensics. ... phenotyping capabilities (predicting appearance and ancestry from DNA ...
(Date:2/1/2016)... Canada , February 1, 2016 ... technological advancements to drive global touchfree intuitive gesture control ... --> Rising sales of consumer electronics coupled ... gesture control market size through ... consumer electronics coupled with new technological advancements to drive ...
(Date:2/1/2016)... , Feb. 1, 2016  Wocket® smart wallet ( www.wocketwallet.com ) ... television personality, Joey Fatone . Las Vegas ... fans. --> Las Vegas , where Joey ... --> The new video ad was filmed at the Consumer Electronics ... at the Wocket booth to meet and greet fans. ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... ... February 09, 2016 , ... Creation Technologies, leading global provider ... Overall Customer Rating Award from Circuits Assembly , today announced its milestone achievement ... Canada, Mexico and China. , The EMS provider, known in the EMS industry ...
(Date:2/9/2016)... ... February 08, 2016 , ... Date and time: March 1, ... the Pennsylvania Biotechnology Center of Bucks County, 3805 Old Easton Road, Doylestown, PA ... will hold an open house for participants to learn about a new Master ...
(Date:2/9/2016)... ... February 09, 2016 , ... Tunnell Consulting, Inc. announced that Frédéric ... he will focus on acquiring new accounts and work closely with existing Tunnell clients ... “Fred brings to our European clients more than 15 years of experience in the ...
(Date:2/9/2016)... ... 2016 , ... PharmApprove announced today the hiring ... for Rare Disorders (NORD). Dorman will lead PharmApprove efforts to work with patients, ... drug regulatory review process. , “Adding Diane Dorman is just the latest in ...
Breaking Biology Technology: